Patents by Inventor Sebastien CAILLE

Sebastien CAILLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salts and crystal forms of omecamtiv mecarbil
    Patent number: 11926592
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Amgen Inc.
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Alisa Golightly
  • SYNTHESIS OF OMECAMTIV MECARBIL
    Publication number: 20230373955
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Application
    Filed: July 26, 2023
    Publication date: November 23, 2023
    Inventors: Sebastien CAILLE, Kyle QUASDORF, Philipp C. ROOSEN, Xianqing SHI, Andrew COSBIE, Fang WANG, Zufan WU, Archana NEERGUNDA, Bin Peter QUAN, Lianxiu GUAN
  • Processes for Preparing a MDM2 Inhibitor
    Publication number: 20230379796
    Abstract: The present invention provides commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates thereof.
    Type: Application
    Filed: August 1, 2023
    Publication date: November 23, 2023
    Inventors: Sebastien Caille, Michael Corbett, Austin Smith
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20230301974
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: May 8, 2023
    Publication date: September 28, 2023
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • Processes for preparing a MDM2 inhibitor
    Patent number: 11753386
    Abstract: The present invention provides commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates thereof.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 12, 2023
    Assignee: Amgen, Inc.
    Inventors: Sebastien Caille, Michael Corbett, Austin Smith
  • Synthesis of omecamtiv mecarbil
    Patent number: 11753394
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: September 12, 2023
    Assignee: AMGEN INC.
    Inventors: Sebastien Caille, Kyle Quasdorf, Philipp C. Roosen, Xianqing Shi, Andrew Cosbie, Fang Wang, Zufan Wu, Archana Neergunda, Bin Peter Quan, Lianxiu Guan
  • Synthesis of omecamtiv mecarbil
    Patent number: 11702380
    Abstract: Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: July 18, 2023
    Assignee: Amgen Inc.
    Inventors: Sebastien Caille, James Murray, Kyle Quasdorf, Hannah Nguyen, Maria Victoria Silva Elipe, Ari Elizabeth Ericson
  • IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND
    Publication number: 20230192682
    Abstract: The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
    Type: Application
    Filed: November 13, 2020
    Publication date: June 22, 2023
    Inventors: Michael Thomas CORBETT, Sebastien CAILLE
  • SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL
    Publication number: 20230108971
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Application
    Filed: September 2, 2022
    Publication date: April 6, 2023
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Alisa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
  • Salts and crystal forms of omecamtiv mecarbil
    Patent number: 11465969
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: October 11, 2022
    Assignees: CYTOKINETICS, INC., AMGEN INC.
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
  • SYNTHESIS OF OMECAMTIV MECARBIL
    Publication number: 20220298099
    Abstract: Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 22, 2022
    Inventors: Sebastien CAILLE, James MURRAY, Kyle QUASDORF, Hannah NGUYEN, Maria Victoria SILVA ELIPE, Ari Elizabeth ERICSON
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20220280496
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: October 13, 2021
    Publication date: September 8, 2022
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • SYNTHESIS OF OMECAMTIV MECARBIL
    Publication number: 20210371397
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 2, 2021
    Inventors: Sebastien Caille, Kyle Quasdorf, Philipp C. Roosen, Xianqing Shi, Andrew Cosbie, Fang Wang, Zufan Wu, Archana Neergunda, Bin Peter Quan, Lianxiu Guan
  • Processes for Preparing a MDM2 Inhibitor
    Publication number: 20210347743
    Abstract: The present invention provides commercial processes for preparing 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3- yl)acetic acid as well as intermediates thereof.
    Type: Application
    Filed: August 30, 2019
    Publication date: November 11, 2021
    Inventors: Sebastien Caille, Michael Corbett, Austin Smith
  • SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL
    Publication number: 20210221771
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 22, 2021
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Ailsa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
  • Synthesis of omecamtiv mecarbil
    Patent number: 11040956
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: June 22, 2021
    Assignee: AMGEN INC.
    Inventors: Sebastien Caille, Kyle Quasdorf, Philipp Roosen, Xianqing Shi, Andrew Cosbie, Fang Wang, Zufan Wu, Archana Neergunda, Bin Peter Quan, Lianxiu Guan
  • SYNTHESIS OF OMECAMTIV MECARBIL
    Publication number: 20200308143
    Abstract: Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 1, 2020
    Inventors: Sebastien Caille, Kyle Quasdorf, Philipp Roosen, Xianqing Shi, Andrew Cosbie, Fang Wang, Zufan Wu, Archana Neergunda, Bin Peter Quan, Lianxiu Guan
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20200281912
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: October 25, 2019
    Publication date: September 10, 2020
    Applicant: AMGEN IINC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNTSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20180092898
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • Processes of making and crystalline forms of a MDM2 inhibitor
    Patent number: 9855259
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 2, 2018
    Assignee: Amgen Inc.
    Inventors: Matthew Bio, Sebastien Caille, Brian Cochran, Yuanqing Fang, Filisaty Vounatsos, Sarah Wortman